UK-based medical device startup Cambridge Heartwear has developed the Heartsense monitor that uses AI to diagnose heart rhythm problems in real-time.
The Heartsense monitor is designed specifically to detect heart disease and atrial fibrillation (AF), an irregular heart rhythm that can lead to heart conditions such as blood clots, stroke and heart failure.
The wirelessly chargeable heart monitor provides continuous monitoring of heart rhythms via electrocardiograms (ECGs). The wearable gathers real-time data of the heart rhythm and streams it wirelessly to the cloud. The data is then automatically diagnosed by AI using algorithms and fed back to the user via an accompanying smartphone app.
When using the device, patients control and own their own heart data, with the option to allow the device to securely acquire and transmit their real-time data to their physician.
The Heartsense monitor was born out of the real-life clinical practice of Cambridge cardiologist and cardiology MIT fellow Dr Rameen Shakur, who is the Founder and CEO of Cambridge Heartwear.
“Our vision behind forming Cambridge Heartwear was to create a bespoke and patient-driven solution to the problem of preventing stroke and heart disease,” said Dr Shakur.
“The technology and clinical care systems we currently have in place are not picking up AF before someone has a stroke and do not enable us to put preventative treatment in place. While there are wearable devices that do general health detection, there is currently no medically-driven device on the market coming out of a clinical practice. There is a critical need for a holistic, multi-input and patient-driven device that takes into account the complex physiology of a patient. We are the first patient-driven AI wearable device born out of real-life clinical practice, not an engineering lab,” continued Dr Shakur.
The Heartsense monitor is currently undergoing clinical trials among top-tier athletic organisations in the UK and the US. Cambridge Heartwear is also providing Heartsense monitors to communities in India and Africa to help prevent heart disease and stroke amongst patients.
The device is expected to be available on the market in early 2019.